Cargando…

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis

BACKGROUND: Considerable clinical heterogeneity in idiopathic pulmonary fibrosis (IPF) suggests the existence of multiple disease endotypes. Identifying these endotypes would improve our understanding of the pathogenesis of IPF and could allow for a biomarker-driven personalised medicine approach. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraven, Luke M, Taylor, Adam R, Molyneaux, Philip L, Maher, Toby M, McDonough, John E, Mura, Marco, Yang, Ivana V, Schwartz, David A, Huang, Yong, Noth, Imre, Ma, Shwu Fan, Yeo, Astrid J, Fahy, William A, Jenkins, R Gisli, Wain, Louise V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643664/
https://www.ncbi.nlm.nih.gov/pubmed/35534152
http://dx.doi.org/10.1136/thoraxjnl-2021-218563
_version_ 1784826567142146048
author Kraven, Luke M
Taylor, Adam R
Molyneaux, Philip L
Maher, Toby M
McDonough, John E
Mura, Marco
Yang, Ivana V
Schwartz, David A
Huang, Yong
Noth, Imre
Ma, Shwu Fan
Yeo, Astrid J
Fahy, William A
Jenkins, R Gisli
Wain, Louise V
author_facet Kraven, Luke M
Taylor, Adam R
Molyneaux, Philip L
Maher, Toby M
McDonough, John E
Mura, Marco
Yang, Ivana V
Schwartz, David A
Huang, Yong
Noth, Imre
Ma, Shwu Fan
Yeo, Astrid J
Fahy, William A
Jenkins, R Gisli
Wain, Louise V
author_sort Kraven, Luke M
collection PubMed
description BACKGROUND: Considerable clinical heterogeneity in idiopathic pulmonary fibrosis (IPF) suggests the existence of multiple disease endotypes. Identifying these endotypes would improve our understanding of the pathogenesis of IPF and could allow for a biomarker-driven personalised medicine approach. We aimed to identify clinically distinct groups of patients with IPF that could represent distinct disease endotypes. METHODS: We co-normalised, pooled and clustered three publicly available blood transcriptomic datasets (total 220 IPF cases). We compared clinical traits across clusters and used gene enrichment analysis to identify biological pathways and processes that were over-represented among the genes that were differentially expressed across clusters. A gene-based classifier was developed and validated using three additional independent datasets (total 194 IPF cases). FINDINGS: We identified three clusters of patients with IPF with statistically significant differences in lung function (p=0.009) and mortality (p=0.009) between groups. Gene enrichment analysis implicated mitochondrial homeostasis, apoptosis, cell cycle and innate and adaptive immunity in the pathogenesis underlying these groups. We developed and validated a 13-gene cluster classifier that predicted mortality in IPF (high-risk clusters vs low-risk cluster: HR 4.25, 95% CI 2.14 to 8.46, p=3.7×10(−5)). INTERPRETATION: We have identified blood gene expression signatures capable of discerning groups of patients with IPF with significant differences in survival. These clusters could be representative of distinct pathophysiological states, which would support the theory of multiple endotypes of IPF. Although more work must be done to confirm the existence of these endotypes, our classifier could be a useful tool in patient stratification and outcome prediction in IPF.
format Online
Article
Text
id pubmed-9643664
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96436642023-06-01 Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis Kraven, Luke M Taylor, Adam R Molyneaux, Philip L Maher, Toby M McDonough, John E Mura, Marco Yang, Ivana V Schwartz, David A Huang, Yong Noth, Imre Ma, Shwu Fan Yeo, Astrid J Fahy, William A Jenkins, R Gisli Wain, Louise V Thorax Interstitial Lung Disease BACKGROUND: Considerable clinical heterogeneity in idiopathic pulmonary fibrosis (IPF) suggests the existence of multiple disease endotypes. Identifying these endotypes would improve our understanding of the pathogenesis of IPF and could allow for a biomarker-driven personalised medicine approach. We aimed to identify clinically distinct groups of patients with IPF that could represent distinct disease endotypes. METHODS: We co-normalised, pooled and clustered three publicly available blood transcriptomic datasets (total 220 IPF cases). We compared clinical traits across clusters and used gene enrichment analysis to identify biological pathways and processes that were over-represented among the genes that were differentially expressed across clusters. A gene-based classifier was developed and validated using three additional independent datasets (total 194 IPF cases). FINDINGS: We identified three clusters of patients with IPF with statistically significant differences in lung function (p=0.009) and mortality (p=0.009) between groups. Gene enrichment analysis implicated mitochondrial homeostasis, apoptosis, cell cycle and innate and adaptive immunity in the pathogenesis underlying these groups. We developed and validated a 13-gene cluster classifier that predicted mortality in IPF (high-risk clusters vs low-risk cluster: HR 4.25, 95% CI 2.14 to 8.46, p=3.7×10(−5)). INTERPRETATION: We have identified blood gene expression signatures capable of discerning groups of patients with IPF with significant differences in survival. These clusters could be representative of distinct pathophysiological states, which would support the theory of multiple endotypes of IPF. Although more work must be done to confirm the existence of these endotypes, our classifier could be a useful tool in patient stratification and outcome prediction in IPF. BMJ Publishing Group 2023-06 2022-05-09 /pmc/articles/PMC9643664/ /pubmed/35534152 http://dx.doi.org/10.1136/thoraxjnl-2021-218563 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Interstitial Lung Disease
Kraven, Luke M
Taylor, Adam R
Molyneaux, Philip L
Maher, Toby M
McDonough, John E
Mura, Marco
Yang, Ivana V
Schwartz, David A
Huang, Yong
Noth, Imre
Ma, Shwu Fan
Yeo, Astrid J
Fahy, William A
Jenkins, R Gisli
Wain, Louise V
Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
title Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
title_full Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
title_fullStr Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
title_full_unstemmed Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
title_short Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
title_sort cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
topic Interstitial Lung Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643664/
https://www.ncbi.nlm.nih.gov/pubmed/35534152
http://dx.doi.org/10.1136/thoraxjnl-2021-218563
work_keys_str_mv AT kravenlukem clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT tayloradamr clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT molyneauxphilipl clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT mahertobym clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT mcdonoughjohne clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT muramarco clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT yangivanav clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT schwartzdavida clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT huangyong clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT nothimre clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT mashwufan clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT yeoastridj clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT fahywilliama clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT jenkinsrgisli clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis
AT wainlouisev clusteranalysisoftranscriptomicdatasetstoidentifyendotypesofidiopathicpulmonaryfibrosis